Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

NCT03557788 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG: Rifaximin Oral Tablet

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]